Autism Spectrum Disorder Therapeutics Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-01-29　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2,390 Mn
2033 年預估規模: USD 3,761 Mn
年複合成長率 CAGR: 6.7%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-01-29頁數 151報告編號 CMI2643

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Autism Spectrum Disorder Therapeutics Market, By Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), By Age Group (Child and Adult), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure. Market Dynamics Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders. However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism. Key features of the study • This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies • Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics • The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts Market Segmentation • Drug Type Insights (Revenue, USD Mn, 2026 - 2033) o Aripiprazole o Risperidone o Melatonin o CM-AT o Bumetanide o Balovaptan • Age Group Insights (Revenue, USD Mn, 2026 - 2033) o Child o Adult • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Mn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  North Africa  Central Africa  South Africa • Key Players Insights o F. Hoffmann-La Roche AG o Neurim Pharmaceuticals, Inc. o Yamo Pharmaceuticals LLC o Servier Laboratories Ltd. o Otsuka Holdings Co. Ltd. o Curemark LLC o Oryzon Genomics S.A. o GW Pharmaceuticals Plc. o Teva Pharmaceutical Industries Ltd. o Zynerba Pharmaceuticals Inc. o STALICLA SA o Novartis AG o Pfizer, Inc. o Bristol Myers Squibb

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Global Autism Spectrum Disorder Therapeutics Market, By Drug Type  Global Autism Spectrum Disorder Therapeutics Market, By Age Group  Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel  Global Autism Spectrum Disorder Therapeutics Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trend 4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2020-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Aripiprazole  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Risperidone  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Melatonin  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o CM-AT  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Bumetanide  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Balovaptan  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) 5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2020-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Child  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Adult  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) 6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2020-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) 7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2020 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Value (USD Mn)  Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Value (USD Mn)  Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Value (USD Mn)  Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Value (USD Mn)  Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Value (USD Mn)  Market Size and Forecast, By Drug Type, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o F. Hoffmann-La Roche AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Neurim Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Yamo Pharmaceuticals LLC  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Servier Laboratories Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Otsuka Holdings Co. Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Curemark LLC  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Oryzon Genomics S.A.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o GW Pharmaceuticals Plc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Teva Pharmaceutical Industries Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Zynerba Pharmaceuticals Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o STALICLA SA  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bristol Myers Squibb  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us

提及公司

F. Hoffmann-La Roche AGNeurim Pharmaceuticals, Inc.Yamo Pharmaceuticals LLCServier Laboratories Ltd.Otsuka Holdings Co. Ltd.Curemark LLCOryzon Genomics S.A.GW Pharmaceuticals Plc.Teva Pharmaceutical Industries Ltd.Zynerba Pharmaceuticals Inc.STALICLA SANovartis AGPfizer, Inc.Bristol Myers Squibb

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們